What is Low-Density Lipoprotein (LDL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is LDL (Low-Density Lipoprotein)?

Low-density lipoprotein (LDL) is the dominant form of atherogenic cholesterol that promotes atherosclerosis and cardiovascular disease. 1

Definition and Structure

  • LDL is a lipoprotein particle that transports cholesterol to peripheral tissues and can deposit in arterial walls, promoting plaque formation 2
  • LDL contains apolipoprotein B (apoB) as its main protein component, with one apoB molecule present on each LDL particle 1
  • LDL can be measured directly, but is usually calculated using the Friedewald formula:
    • In mmol/L: LDL cholesterol = total cholesterol – HDL cholesterol – (0.45 × triglycerides) 1
    • In mg/dL: LDL cholesterol = total cholesterol – HDL cholesterol – (0.2 × triglycerides) 1

Physiological Role

  • LDL serves as the primary carrier of cholesterol in the bloodstream, delivering it to cells throughout the body 1
  • LDL is removed from circulation by LDL receptors on cell surfaces through receptor-mediated endocytosis 3
  • The liver contains the majority of physiologically important LDL receptors, where their number is regulated by the cholesterol content of hepatocytes 3

LDL and Cardiovascular Risk

  • LDL is a proven causative factor for developing coronary artery disease (CAD), with a log-linear correlation between LDL-C levels and CAD risk 1, 4
  • LDL cholesterol is the primary target of cholesterol-lowering therapy in most guidelines, with the relationship between LDL reduction and cardiovascular risk following "the lower, the better" principle 2
  • For each 1.0 mmol/L (~40 mg/dL) reduction in LDL cholesterol, major vascular events and all-cause mortality are reduced by 22% and 10%, respectively 1

LDL Heterogeneity

  • LDL particles are heterogeneous in size, density, and chemical composition 5
  • Small, dense LDL (sdLDL) particles possess stronger atherogenic ability compared to larger LDL subfractions 5, 6
  • The presence of small, dense LDL is part of an "atherogenic lipoprotein phenotype" that includes elevated triglycerides and low HDL cholesterol 6
  • When plasma triglycerides exceed approximately 133 mg/dL (1.5 mmol/L), this favors the formation of small, dense LDL from larger, less dense species 6

Clinical Significance and Target Levels

  • The American College of Cardiology recommends the following LDL cholesterol categories: 2

    • Very high: ≥175 mg/dL
    • High: 150-174 mg/dL
    • Borderline high: 125-149 mg/dL
    • Borderline low: 100-124 mg/dL
    • Low: 75-99 mg/dL
    • Very low: 50-74 mg/dL
    • Optimal: <100 mg/dL
  • In high-risk patients, an LDL cholesterol goal of <1.8 mmol/L (less than 70 mg/dL) or a ≥50% LDL cholesterol reduction is recommended 1

  • For patients at moderate risk, an LDL cholesterol goal of <3.0 mmol/L (less than 115 mg/dL) should be considered 1

Beyond LDL Cholesterol

  • Non-HDL cholesterol (total cholesterol minus HDL cholesterol) may be a better predictor of cardiovascular risk than LDL alone, especially in patients with elevated triglycerides 1, 2
  • Apolipoprotein B (apoB) may more directly measure circulating atherogenic lipoproteins than LDL cholesterol 1
  • The apoB:apoA1 ratio is one of the strongest risk markers for cardiovascular disease, though it is not yet established as a treatment goal 1

Therapeutic Implications

  • Statins are the first-line therapy for LDL reduction, lowering LDL by 35-55% depending on type and dose 2, 7
  • Other LDL-lowering options include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors 2
  • Atorvastatin and other statins are indicated to reduce LDL-C in adults with primary hyperlipidemia and in patients with heterozygous familial hypercholesterolemia 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.